Publications

Journals

• Chaidos A; Patterson S; Szydlo R; Chaudhry MS; Dazzi F; Kanfer E; Macdonald D; Marin D; et alMilojkovic D; Pavlu J; Davis J; Rahemtulla A; Rezvani K; Goldman J; Roberts I; Apperley J; Karadimitris A. (27 Feb 2012). Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood. DOI.
• Fan H; Cao P; Game DS; Dazzi F; Liu Z; Jiang S. (1 Dec 2011). Regulatory T cell therapy for the induction of clinical organ transplantation tolerance. SEMINARS IN IMMUNOLOGY. 23:453-461. Author weblink DOI.
• Capelli C; Gotti E; Morigi M; Rota C; Weng L; Dazzi F; Spinelli O; Cazzaniga G; et alTrezzi R; Gianatti A; Rambaldi A; Golay J; Introna M. (1 Jan 2011). Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. CYTOTHERAPY. 13:786-801. DOI.
• Rezvani K; Kanfer EJ; Marin D; Gabriel I; Rahemtulla A; Taylor A; Macdonald D; Dazzi F; et alMilojkovic D; Foroni L; Pavlu J; Sargent J; Le Dieu R; Goldman JM; Apperley J; Szydlo R. (Feb 2012). EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure. Biol Blood Marrow Transplant. 18:235-240. DOI.
• Marigo I; Dazzi F. (Nov 2011). The immunomodulatory properties of mesenchymal stem cells. Semin Immunopathol. 33:593-602. DOI.
• Trento C; Dazzi F. (15 Jan 2011). Mesenchymal stem cells and innate tolerance: biology and clinical applications. SWISS MEDICAL WEEKLY. 141:24-27. Author weblink DOI.
• Dazzi F; Krampera M. (Mar 2011). Mesenchymal stem cells and autoimmune diseases. Best Pract Res Clin Haematol. 24:49-57. DOI.
• Lymperi S; Ersek A; Ferraro F; Dazzi F; Horwood NJ. (3 Feb 2011). Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo. Blood. 117:1540-1549. DOI.
• Trento C; Dazzi F. (2010). Mesenchymal stem cells and innate tolerance: biology and clinical applications. Swiss Med Wkly. 140:w13121. DOI.
• Jaganathan BG; Tisato V; Vulliamy T; Dokal I; Marsh J; Dazzi F; Bonnet D. (1 Oct 2010). Effects of MSC co-injection on the reconstitution of aplastic anemia patient following hematopoietic stem cell transplantation. LEUKEMIA. 24:1791-1795. Author weblink DOI.
• Ibrahim AR; Paliompeis C; Bua M; Milojkovic D; Szydlo R; Khorashad JS; Foroni L; Reid A; et alde Lavallade H; Rezvani K; Dazzi F; Apperley JF; Goldman JM; Marin D. (16 Dec 2010). Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 116:5497-5500. DOI.
• Weng L; Williams RO; Vieira PL; Screaton G; Feldmann M; Dazzi F. (Aug 2010). The therapeutic activity of low-dose irradiation on experimental arthritis depends on the induction of endogenous regulatory T cell activity. Ann Rheum Dis. 69:1519-1526. DOI.
• Chalandon Y; Passweg JR; Schmid C; Olavarria E; Dazzi F; Simula MP; Ljungman P; Schattenberg A; et alde Witte T; Lenhoff S; Jacobs P; Volin L; Iacobelli S; Finke J; Niederwieser D; Guglielmi C. (1 Mar 2010). Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT. BONE MARROW TRANSPLANTATION. 45:558-564. DOI.
• Vianello F; Villanova F; Tisato V; Lymperi S; Ho KK; Gomes AR; Marin D; Bonnet D; et alApperley J; Lam EW; Dazzi F. (Jul 2010). Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica. 95:1081-1089. DOI.
• Uprichard J; Dazzi F; Apperley JF; Laffan MA. (1 Jan 2010). Haemopoietic stem cell transplantation induces tolerance to donor antigens but not to foreign FVIII peptides. HAEMOPHILIA. 16:143-147. Author weblink DOI.
• Dinesen L; Wang A; Vianello F; Tait P; Leen E; Davis J; Dazzi F; Ghosh S. (1 Oct 2009). Mesenchymal stem cells administered via novel selective mesenteric artery cannulation for the treatment of severe refractory Crohns disease. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. 24:A230-A231. Author weblink.
• Garland P; Dazzi F; Marin D. (Feb 2010). Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML. Bone Marrow Transplant. 45:395-396. DOI.
• Schaefer R; Dominici M; Mueller I; Horwitz E; Asahara T; Bulte JWM; Bieback K; Le Blanc K; et alBuehring HJ; Capogrossi MC; Dazzi F; Gorodetsky R; Henschler R; Handgretinger R; Kajstura J; Kluger PJ; Lange C; von Luettichau I; Mertsching H; Schrezenmeier H; Sievert KD; Strunk D; Verfaillie C; Northoff H. (1 Jan 2009). Basic research and clinical applications of non-hematopoietic stem cells, 4-5 April 2008, Tubingen, Germany. CYTOTHERAPY. 11:245-255. Author weblink DOI.
• Haniffa MA; Collin MP; Buckley CD; Dazzi F. (1 Feb 2009). Mesenchymal stem cells: the fibroblasts' new clothes?. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. 94:258-263. Author weblink DOI.
• Mueller I; Lymperi S; Dazzi F. (1 Dec 2008). Mesenchymal stem cell therapy for degenerative inflammatory disorders. CURRENT OPINION IN ORGAN TRANSPLANTATION. 13:639-644. Author weblink DOI.
• Marin D; Milojkovic D; Olavarria E; Khorashad JS; de lavallade H; Reid AG; Foroni L; Rezvani K; et alBua M; Dazzi F; Pavlu J; Klammer M; Kaeda JS; Goldman JM; Apperley JF. (1 Dec 2008). European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. BLOOD. 112:4437-4444. Author weblink DOI.
• Weng L; Addey C; Warrens AN; Dyson J; Chai JG; Dazzi F. (15 Nov 2008). Dissection of effector pathways in the host-versus-graft response to bone marrow transplantation. Transplantation. 86:1311-1314. DOI.
• Karlsson H; Samarasinghe S; Ball LM; Sundberg B; Lankester AC; Dazzi F; Uzunel M; Rao K; et alVeys P; Le Blanc K; Ringden O; Amrolia PJ. (1 Aug 2008). Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. BLOOD. 112:532-541. Author weblink DOI.
• Tyndall A; Dazzi F. (1 Jun 2008). Chronic GVHD as an autoimmune disease. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY. 21:281-289. Author weblink DOI.
• Dazzi F; Marelli-Berg FM. (1 Jun 2008). Mesenchymal stem cells for graft-versus-host disease: Close encounters with T cells. EUROPEAN JOURNAL OF IMMUNOLOGY. 38:1479-1482. Author weblink DOI.
• Ramasamy R; Tong CK; Seow HF; Vidyadaran S; Dazzi F. (Feb 2008). The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol. 251:131-136. DOI.
• Vianello F; Dazzi F. (1 Mar 2008). Mesenchymal stem cells for graft-versus-host disease: a double edged sword?. LEUKEMIA. 22:463-465. Author weblink DOI.
• Lymperi S; Horwood N; Marley S; Gordon MY; Cope AP; Dazzi F. (1 Feb 2008). Strontium can increase some osteoblasts without increasing hematopoietic stem cells. BLOOD. 111:1173-1181. Author weblink DOI.
• Marelli-Berg FM; Cannella L; Dazzi F; Mirenda V. (1 Jan 2008). The highway code of T cell trafficking. JOURNAL OF PATHOLOGY. 214:179-189. Author weblink DOI.
• Levicar N; Pai M; Habib NA; Tait P; Jiao LR; Marley SB; Davis J; Dazzi F; et alSmadja C; Jensen SL; Nicholls JP; Apperley JF; Gordon MY. (Feb 2008). Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+ cells in patients with chronic liver disease. Cell Prolif. 41 Suppl 1:115-125. DOI.
• Dazzi F; Fozza C. (1 Sep 2007). Reply to 'Splenectomy status of the patient may have impact on response to donor lymphocyte infusions' by Duygu Uckan-Cetinkaya et al. LEUKEMIA. 21:2050-2051. Author weblink DOI.
• Tisato V; Naresh K; Girdlestone J; Navarrete C; Dazzi F. (1 Sep 2007). Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. LEUKEMIA. 21:1992-1999. Author weblink DOI.
• Dazzi F; Horwood NJ. (Nov 2007). Potential of mesenchymal stem cell therapy. Curr Opin Oncol. 19:650-655. DOI.
• Jones S; Horwood N; Cope A; Dazzi F. (1 Sep 2007). The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol. 179:2824-2831.
• Dazzi F; van Laar JM; Cope A; Tyndall A. (1 Jan 2007). Cell therapy for autoimmune diseases. ARTHRITIS RESEARCH & THERAPY. 9. Author weblink DOI.
• Gordon MY; Dazzi F; Marley SB; Lewis JL; Nguyen D; Grand FH; Davidson RJ; Goldman JM. (Apr 1999). Cell biology of CML cells. LEUKEMIA. 13:S65-S71.
• Dazzi F. (Feb 2002). Monitoring of minimal residual disease after allografting: A requirement to guide DLI treatment?. ANN HEMATOL. 81:S29-S30.
• Weng L; Dyson J; Dazzi F. (15 May 2007). Low-intensity transplant regimens facilitate recruitment of donor-specific regulatory T cells that promote hematopoietic engraftment. Proc Natl Acad Sci U S A. 104:8415-8420. DOI.
• Dazzi F; Fozza C. (Jun 2007). Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment. Best Pract Res Clin Haematol. 20:311-327. DOI.
• Simula MP; Marktel S; Fozza C; Kaeda J; Szydlo RM; Nadal E; Bua M; Rahemtulla A; et alKanfer E; Marin D; Olavarria E; Goldman JM; Apperley JF; Dazzi F. (May 2007). Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia. 21:943-948. DOI.
• Fozza C; Szydlo RM; Abdel-Rehim MM; Nadal E; Goldman JM; Apperley JF; Dazzi F. (Mar 2007). Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. Br J Haematol. 136:833-836. DOI.
• Fozza C; Nadal E; Longinotti M; Dazzi F. (Feb 2007). T-cell receptor repertoire usage after allografting differs between CD4+CD25+ regulatory T cells and their CD4+CD25- counterpart. Haematologica. 92:206-214.
• Zhang Z; Gorman CL; Vermi AC; Monaco C; Foey A; Owen S; Amjadi P; Vallance A; et alMcClinton C; Marelli-Berg F; Isomäki P; Russell A; Dazzi F; Vyse TJ; Brennan FM; Cope AP. (15 May 2007). TCRzetadim lymphocytes define populations of circulating effector cells that migrate to inflamed tissues. Blood. 109:4328-4335. DOI.
• Ramasamy R; Fazekasova H; Lam EW; Soeiro I; Lombardi G; Dazzi F. (15 Jan 2007). Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation. 83:71-76. DOI.
• Nadal E; Garin M; Kaeda J; Apperley J; Lechler R; Dazzi F. (Mar 2007). Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia. 21:472-479. DOI.
• Ramasamy R; Lam EW; Soeiro I; Tisato V; Bonnet D; Dazzi F. (Feb 2007). Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia. 21:304-310. DOI.
• Gordon MY; Levicar N; Pai M; Bachellier P; Dimarakis I; Al-Allaf F; M'Hamdi H; Thalji T; et alWelsh JP; Marley SB; Davies J; Dazzi F; Marelli-Berg F; Tait P; Playford R; Jiao L; Jensen S; Nicholls JP; Ayav A; Nohandani M; Farzaneh F; Gaken J; Dodge R; Alison M; Apperley JF; Lechler R; Habib NA. (Jul 2006). Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells. 24:1822-1830. DOI.
• Kaeda J; O'Shea D; Szydlo RM; Olavarria E; Dazzi F; Marin D; Saunders S; Khorashad JS; et alCross NC; Goldman JM; Apperley JF. (15 May 2006). Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood. 107:4171-4176. DOI.
• Dazzi F; Ramasamy R; Glennie S; Jones SP; Roberts I. (May 2006). The role of mesenchymal stem cells in haemopoiesis. Blood Rev. 20:161-171. DOI.
• Du Roure C; Takács K; Maxwell PH; Roberts I; Dazzi F; Cannella L; Merkenschlager M; Fisher AG. (Mar 2006). Correction of severe anaemia using immuno-regulated gene therapy is achieved by restoring the early erythroblast compartment. Br J Haematol. 132:608-614. DOI.
• Cummins M; Cwynarski K; Marktel S; Dazzi F; Cavenagh J; Clark RE; Holyoake TL; Milligan D; et alParker A; Russell NH; Marks DI. (1 Dec 2005). Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the clinical trials committee of the British Society of Blood & Marrow Transplantation (BSBMT). BONE MARROW TRANSPLANTATION. 36:1065-1069. Author weblink DOI.
• Krampera M; Pasini A; Rigo A; Scupoli MT; Tecchio C; Malpeli G; Scarpa A; Dazzi F; et alPizzolo G; Vinante F. (1 Jul 2005). HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. BLOOD. 106:59-66. Author weblink DOI.
• Laylor R; Dewchand H; Simpson E; Dazzi F. (15 Jun 2005). Engraftment of allogeneic hematopoietic stem cells requires both inhibition of host-versus-graft responses and 'space' for homeostatic expansion. Transplantation. 79:1484-1491.
• Glennie S; Soeiro I; Dyson PJ; Lam EW; Dazzi F. (1 Apr 2005). Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 105:2821-2827. DOI.
• Marin D; Kaeda J; Szydlo R; Saunders S; Fleming A; Howard J; Andreasson C; Bua M; et alOlavarria E; Rahemtulla A; Dazzi F; Kanfer E; Goldman JM; Apperley JF. (Apr 2005). Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia. 19:507-512. DOI.
• Cwynarski K; Melo JV; Dazzi F. (1 Mar 2005). Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia? Reply. LEUKEMIA. 19:457-457. Author weblink DOI.
• Cwynarski K; Laylor R; Macchiarulo E; Goldman J; Lombardi G; Melo JV; Dazzi F. (Aug 2004). Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia. 18:1332-1339. DOI.
• Laylor R; Cannella L; Simpson E; Dazzi F. (Jul 2004). Minor histocompatibility antigens and stem cell transplantation. Vox Sang. 87 Suppl 2:11-14. DOI.
• Nadal E; Fowler A; Kanfer E; Apperley J; Goldman J; Dazzi F. (Feb 2004). Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Exp Hematol. 32:218-223. DOI.
• James E; Chai JG; Dewchand H; Macchiarulo E; Dazzi F; Simpson E. (1 Jul 2003). Multiparity induces priming to male-specific minor histocompatibility antigen, HY, in mice and humans. Blood. 102:388-393. DOI.
• Gao L; Xue SA; Hasserjian R; Cotter F; Kaeda J; Goldman JM; Dazzi F; Stauss HJ. (15 May 2003). Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation. 75:1429-1436. DOI.
• Krampera M; Glennie S; Dyson J; Scott D; Laylor R; Simpson E; Dazzi F. (1 May 2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 101:3722-3729. DOI.
• Dong R; Cwynarski K; Entwistle A; Marelli-Berg F; Dazzi F; Simpson E; Goldman JM; Melo JV; et alLechler RI; Bellantuono I; Ridley A; Lombardi G. (1 May 2003). Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood. 101:3560-3567. DOI.
• Marktel S; Marin D; Foot N; Szydlo R; Bua M; Karadimitris A; De Melo VA; Kotzampaltiris P; et alDazzi F; Rahemtulla A; Olavarria E; Apperley JF; Goldman JM. (Mar 2003). Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica. 88:260-267.
• Gilleece MH; Dazzi F. (Jan 2003). Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk Lymphoma. 44:23-28. DOI.
• Bellantuono I; Gao L; Parry S; Marley S; Dazzi F; Apperley J; Goldman JM; Stauss HJ. (15 Nov 2002). Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood. 100:3835-3837. DOI.
• Dazzi F; Szydlo RM; Apperley JF; Goldman JM. (1 Oct 2002). Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions. Blood. 100:2673-2674.
• Dazzi F; Szydlo RM; Apperley JF; Goldman JM. (1 Oct 2002). To the editor: Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions. BLOOD. 100:2673-2674. Author weblink DOI.
• Simpson E; Scott D; James E; Lombardi G; Cwynarski K; Dazzi F; Millrain M; Dyson PJ. (Aug 2002). Minor H antigens: genes and peptides. Transpl Immunol. 10:115-123.
• Guglielmi C; Arcese W; Dazzi F; Brand R; Bunjes D; Verdonck LF; Schattenberg A; Kolb HJ; et alLjungman P; Devergie A; Bacigalupo A; Gomez M; Michallet M; Elmaagacli A; Gratwohl A; Apperley J; Niederwieser D. (15 Jul 2002). Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood. 100:397-405.
• Olavarria E; Craddock C; Dazzi F; Marin D; Marktel S; Apperley JF; Goldman JM. (15 May 2002). Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood. 99:3861-3862.
• Mughal TI; Yong A; Szydlo RM; Dazzi F; Olavarria E; van Rhee F; Kaeda J; Cross NC; et alCraddock C; Kanfer E; Apperley J; Goldman JM. (Dec 2001). Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol. 115:569-574.
• Guglielmi C; Arcese W; Dazzi F; Bunjes D; Verdonck LF; Schattenberg A; Kolb HJ; Ljungman P; et alDevergie A; Bacigalupo A; Gomez M; Michallet M; Elmaagacli A; Gratwohl A; Apperley J; Niederwieser D. (16 Nov 2001). Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: The first dose decides outcome. BLOOD. 98:727A-727A. Author weblink.
• Cwynarski K; Laylor R; Melo JV; Dazzi F. (16 Nov 2001). STI571 inhibits the activaiton and proliferation of normal T lymphocytes. BLOOD. 98:256B-257B. Author weblink.
• Millrain M; Chandler P; Dazzi F; Scott D; Simpson E; Dyson PJ. (1 Oct 2001). Examination of HY response: T cell expansion, immunodominance, and cross-priming revealed by HY tetramer analysis. J Immunol. 167:3756-3764.
• Simpson E; Scott D; James E; Lombardi G; Cwynarski K; Dazzi F; Millrain JM; Dyson PJ. (Oct 2001). Minor H antigens: genes and peptides. Eur J Immunogenet. 28:505-513.
• Cwynarski K; Goulding R; Pocock C; Dazzi F; Craddock C; Kaeda J; Olavarria E; Kanfer E; et alApperley J; Lawler M; Goldman JM. (Sep 2001). Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions. Bone Marrow Transplant. 28:581-586. DOI.
• Dazzi F; Simpson E; Goldman JM. (Jul 2001). Minor antigen solves major problem. Nat Med. 7:769-770. DOI.
• Olavarria E; Kanfer E; Szydlo R; Kaeda J; Rezvani K; Cwynarski K; Pocock C; Dazzi F; et alCraddock C; Apperley JF; Cross NC; Goldman JM. (15 Mar 2001). Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 97:1560-1565.
• Craddock C; Szydlo RM; Dazzi F; Olavarria E; Cwynarski K; Yong A; Brookes P; de la Fuente J; et alKanfer E; Apperley JF; Goldman JM. (Jan 2001). Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol. 112:228-236.
• Bellantuono I; Macchiarulo E; Gao LQ; Dazzi F; Cerundolo V; Marley SB; Gordon MY; Goldman JM; et alStauss HJ. (16 Nov 2000). Immunoresponse to Wilms Tumor antigen-1 (WT-1) in CML patients. BLOOD. 96:144A-144A. Author weblink.
• Guglielmi C; Apperley J; Arcese W; Bunjes D; Dazzi F; Schattenberg A; Verdonck LF; Niederwieser D; et alKolb HJ. (16 Nov 2000). Risk assessment in patients with Ph plus CML treated with donor lymphocyte transfusion at relapse after allogeneic stem cell transplant. BLOOD. 96:545A-545A. Author weblink.
• Dazzi F; Chandler P; Dewchand H; Millrain M; Laylor R; Picard J; Stauss H; Goldman J; et alSimpson E. (16 Nov 2000). The host-versus-graft (HvG) reaction in allogeneic stem cell transplantation (SCT): Donor-recipient chimerism is not associated with clonal deletion of HvG effector T cells. BLOOD. 96:374A-374A. Author weblink.
• Dazzi F; Szydlo RM; Cross NC; Craddock C; Kaeda J; Kanfer E; Cwynarski K; Olavarria E; et alYong A; Apperley JF; Goldman JM. (15 Oct 2000). Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 96:2712-2716.
• Dazzi F; Szydlo RM; Cross NCP; Craddock C; Kaeda J; Kanfer E; Cwynarski K; Olavarria E; et alYong A; Apperley JF; Goldman JM. (15 Oct 2000). Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. BLOOD. 96:2612-2616.
• Craddock C; Szydlo RM; Klein JP; Dazzi F; Olavarria E; van Rhee F; Pocock C; Cwynarski K; et alApperley JF; Goldman JM. (1 Jul 2000). Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood. 96:86-90.
• Dazzi F; Szydlo RM; Goldman JM. (1 May 2000). Response - Neither age nor mobilization likely to have effect. BLOOD. 95:2995-2995. Author weblink.
• Dazzi F; Szydlo RM; Craddock C; Cross NC; Kaeda J; Chase A; Olavarria E; van Rhee F; et alKanfer E; Apperley JF; Goldman JM. (1 Jan 2000). Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 95:67-71.
• Dazzi F; Hasserjian R; Gordon MY; Boecklin F; Cotter F; Corbo M; Capelli D; Goldman JM. (2000). Normal and chronic phase CML hematopoietic cells repopulate NOD/SCID bone marrow with different kinetics and cell lineage representation. Hematol J. 1:307-315. DOI.
• Pocock C; Craddock C; Szydlo R; Klein J; Dazzi F; Olavarria E; Cwynarski K; Apperley J; et alGoldman J. (15 Nov 1999). 'Current leukemia free survival': A novel method for assessing results of allogeneic stem cell transplantation for CML that takes account of the impact of donor lymphocyte infusions in the treatment of relapse. BLOOD. 94:161A-161A. Author weblink.
• Olavarria E; Kaeda J; Carnicero F; Szydlo R; Cross N; Dazzi F; Rezvani K; Johnston R; et alCwynarski K; Craddock C; Kanfer E; Apperley J; Goldman J. (15 Nov 1999). Early detection of BCR/ABL transcripts by RT-PCR predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. BLOOD. 94:632A-632A. Author weblink.
• Dazzi F; Cwynarski K; Craddock C; Szydlo R; Kanfer E; Olavarria E; Apperley JF; Goldman JM. (15 Nov 1999). Factors influencing acute GVHD after donor lymphocyte infusion. BLOOD. 94:669A-669A. Author weblink.
• Cwynarski K; Dazzi F; Cross NCP; Yong A; Craddock C; Kaeda J; Olavarria E; Kanfer E; et alApperley JF; Goldman JM. (15 Nov 1999). Response to donor lymphocyte infusions (DLI) of patients with CML in relapse after allografting: A long-term follow-up study using RT-PCR. BLOOD. 94:669A-669A. Author weblink.
• Cwynarski K; Craddock C; Dazzi F; Szydlo R; Olavarria E; Kaeda J; Apperley J; Goldman J. (15 Nov 1999). T-cell depletion plus adoptive immunotherapy with donor lymphocyte infusions as a strategy to treat patients with chronic myeloid leukemia undergoing stem cell transplantation from volunteer unrelated donors. BLOOD. 94:567A-567A. Author weblink.
• Dazzi F; Goldman J. (Nov 1999). Donor lymphocyte infusions. Curr Opin Hematol. 6:394-399.
• Dazzi F; Szydlo RM; Goldman JM. (Oct 1999). Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol. 27:1477-1486.
• Craddock C; Dazzi F; Szydlo R; Cwynarski K; Olavarria E; Brookes P; Kanfer E; Apperley J; et alGoldman J. (1 Apr 1999). Impact of donor leucocyte infusions on outcome after T cell depleted volunteer unrelated donor (VUD) bone marrow transplantation in patients with CML. BRITISH JOURNAL OF HAEMATOLOGY. 105:32-32. Author weblink.
• Swan NG; Olavarria E; Dazzi F. (1 Mar 1999). An update of the Hammersmith DLI programme and discussion of nursing issues. BONE MARROW TRANSPLANTATION. 23:S269-S269. Author weblink.
• Dazzi F; Craddock C; Szydlo R; Kaeda J; Kanfer E; Cross NCP; Apperley J; Goldman JM. (1 Mar 1999). Donor lymphocyte infusion (DLI) for relapse of chronic myeloid leukemia (CML) after allogeneic stem cell transplant (SCT): Factors influencing the effective cell dose (ECD). BONE MARROW TRANSPLANTATION. 23:S43-S43. Author weblink.
• Dazzi F; Boecklin F; Hasserjian R; Cotter F; Corbo M; Capelli D; Gordon MY; Goldman JM. (1 Mar 1999). Normal and chronic phase CML hematopoietic cells repopulate NOD/SCID bone marrow with different kinetics and differentiation pattern. BONE MARROW TRANSPLANTATION. 23:S58-S58. Author weblink.
• Dazzi F; Szydlo RM; Craddock C; Olavarria E; Kaeda J; van Rhee F; Cross NCP; Apperley JF; et alGoldman JM. (15 Nov 1998). Adoptive immunotherapy for patients who relapse after allografting for chronic myeloid leukemia: A comparison of two regimens for donor lymphocyte infusion. BLOOD. 92:653A-653A. Author weblink.
• Dazzi F; Craddock C; Szydlo R; Kaeda J; Montefusco V; Kanfer E; Cross NCP; Apperley J; et alGoldman JM. (15 Nov 1998). Adoptive immunotherapy with donor lymphocytes for relapse of chronic myeloid leukemia (CML) after allogeneic stem cell transplant (SCT): Factor influencing the effective cell dose (ECD). BLOOD. 92:494A-494A. Author weblink.
• Craddock C; Dazzi F; Szydlo RM; Olavarria E; Cross NCP; van Rhee F; Kanfer E; Apperley JF; et alGoldman JM. (15 Nov 1998). Donor lymphocyte infusions produce durable molecular remission in patients who relapse after allografting for CML in chronic phase: The consequent need to reassess the definition of leukemia free survival. BLOOD. 92:654A-654A. Author weblink.
• Dazzi F; Hasserjian R; Feldmann G; Capelli D; Cotter F; Corbo M; Boecklin F; Gordon MY; et alGoldman JM. (15 Nov 1998). Philadelphia-positive mast cell differentiation of CD34+ cells from chronic phase CML in NOD/SCID mice: Potential for predicting duration of chronic phase. BLOOD. 92:243B-243B. Author weblink.
• Apperley JF; Dazzi F; Craddock C; Goldman JM. (Oct 1998). Immunotherapy for chronic myeloid leukaemia. Hematol Cell Ther. 40:229-232.
• Dazzi F; Capelli D; Hasserjian R; Cotter F; Corbo M; Poletti A; Chinswangwatanakul W; Goldman JM; et alGordon MY. (15 Aug 1998). The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology. Blood. 92:1390-1396.
• Tison T; Dazzi F; Gorza L; Rosato A; Radossi P; Girolami A; Ware J. (1 Jul 1998). Anti-human FVIII antibodies generated in the mouse by subcutaneous versus intravenous FVIII injection recognise different epitopes in the antigenic moiety. BRITISH JOURNAL OF HAEMATOLOGY. 102:15-15. Author weblink.
• Dazzi F; Kaeda J; Kanfer E; Apperley JF; Goldman JM. (1 Jul 1998). Interleukin-2 may induce complete remission in patients who respond only partially to donor lymphocyte infusion (DLI) for relapse following allogeneic bone marrow transplantation. BRITISH JOURNAL OF HAEMATOLOGY. 102:287-287. Author weblink.
• Olavarria E; Murphy K; Dazzi F; Craddock C; Philpott NJ; Apperley JF; Kanfer E; Goldman JM. (1 Jul 1998). Low incidence of GVHD using donor lymphocyte infusions (DLI) with an escalating dose protocol. BRITISH JOURNAL OF HAEMATOLOGY. 102:86-86. Author weblink.
• Dazzi F; Capelli D; Hasserjian R; Cotter F; Corbo M; Gordon MY; Goldman JM. (1 Jul 1998). Philadelphia-positive mast cell differentiation of CD34+ chronic phase cml cells after longterm engraftment in NOD/SCID mice. BRITISH JOURNAL OF HAEMATOLOGY. 102:182-182. Author weblink.
• van Rhee F; Savage D; Blackwell J; Orchard K; Dazzi F; Lin F; Chase A; Bungey J; et alCross NC; Apperley J; Szydlo R; Goldman JM. (May 1998). Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant. 21:1055-1061. DOI.
• Olavarria E; Murphy K; Dazzi F; Craddock C; Philpott NJ; Apperley JF; Kanfer E; Goldman JM. (1 May 1998). Low incidence of GVHD using donor lymphocyte infusion (DLI) with an escalating dose protocol. BRITISH JOURNAL OF HAEMATOLOGY. 101:69-69. Author weblink.
• Dazzi F; Raanani P; van Rhee F; Szydlo R; Olavarria E; Kaeda J; Apperley JF; Cross NCP; et alGoldman JM. (1 Mar 1998). Donor lymphocyte infusion (DLI) for relapse of CML after allo-BMT: Comparison of two regimens. BONE MARROW TRANSPLANTATION. 21:S70-S70. Author weblink.
• Kaeda JS; Dazzi F; Baker P; Raanani P; Kanfer E; Apperley JF; Cross NCP; Goldman JM. (1 Mar 1998). Escalating doses of DLI identify a subset of CML patients in relapse after allografting in whom only a partial or transient response is achieved. BONE MARROW TRANSPLANTATION. 21:S71-S71. Author weblink.
• Raanani P; Dazzi F; Sohal J; Szydlo RM; van Rhee F; Reiter A; Lin F; Goldman JM; et alCross NC. (Dec 1997). The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol. 99:945-950.
• Olavarria E; Dazzi F; Craddock C; Murphy KM; Philpott NJ; Kanfer E; Apperley JF; Goldman JM. (15 Nov 1997). Donor lymphocyte infusions (DLI) for treatment of CML in relapse after allogeneic BMT: Low incidence of GVHD using an escalation dose protocol. BLOOD. 90:2621-2621. Author weblink.
• Dazzi F; Gordon M; Chinswangwatanakul W; Cotter F; Evans M; Hasserjian R; Grand F; Goldman JM. (15 Nov 1997). Engraftment of CML cells in NOD/SCID mice: Potential for characterizing phase of disease. BLOOD. 90:362-362. Author weblink.
• Tison T; Dazzi F; Gorza L; Rosato AP; Radossi P; Girolami A; Ware J. (15 Nov 1997). Generation of anti-human FVIII antibodies in mouse: Epitope recognition varies with the route of administration. A potential for escaping FVII-inhibitors. BLOOD. 90:146-146. Author weblink.
• Craddock C; Szydlo R; Olavarria E; Dazzi F; VanRhee F; Apperley J; Goldman J. (15 Nov 1997). Leukemia free survival after allogeneic transplantation for chronic myeloid leukemia: Effect of reclassifying responders to donor lymphocyte infusion as ''currently free of leukemia''. BLOOD. 90:4449-4449. Author weblink.
• Dazzi F; Raanani P; vanRhee F; Olavarria E; Murphy KM; Philpott NJ; Apperley JF; Cross NCP; et alGoldman JM. (15 Nov 1997). Responses to donor lymphocyte infusion (DLI) in CML patients in relapse after BMT may be partial and transient: Further evidence for a dose-reponse effect. BLOOD. 90:2307-2307. Author weblink.
• Raanani P; Dazzi F; Sohal J; Szydlo RM; vanRhee F; Reiter A; Lin F; Apperley JF; et alGoldman JM; Cross NCP. (15 Nov 1997). The incidence, kinetics and durability of response to donor leukocyte transfusions for CML patients who relapse after BMT. BLOOD. 90:2443-2443. Author weblink.

Chapters in books

• Dazzi F; Stauss HJ. Donor lymphocyte infusions. 385-399. (2001).

Conferences

• Pavlu J; Rezvani K; Kishore B; Chakrabartty J; Shah R; Auner HW; Milojkovic D; Marin D; et alRahemtulla A; MacDonald DH; Kanfer EJ; Dazzi F; Goldman JM; Apperley JF; Szydlo RM. Optimising patient selection for allogeneic stem cell transplantation: prediction of non-relapse mortality and survival. 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), 1 Apr 2012 - 4 Apr 2012. 47:S27-S28. NATURE PUBLISHING GROUP (1 Apr 2012). Author weblink.
• Innes AJ; Lurkins J; Szydlo RM; Guerra A; Milojkovic D; Pavlu J; Kanfer EJ; Marin D; et alMacDonald D; Rahemtulla A; Loaiza S; Kirschke S; Rezvani K; Goldman J; Apperley JF; Dazzi F. The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, 10 Dec 2011 - 13 Dec 2011. 118:1752-1752. AMER SOC HEMATOLOGY (18 Nov 2011). Author weblink.
• Chaidos A; Szydlo RM; Kanfer EJ; Dazzi F; MacDonald DH; Marin D; Milojkovic D; Pavlu J; et alDavis J; Rezvani K; Rahemtulla A; Roberts I; Apperley JF; Karadimitris A. High Frequency and Cell Dose of Invariant NKT Cells In the Graft Are Associated with Lack of Clinically Significant Acute Gvhd In T Cell-Replete Sibling Allografts. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), 4 Dec 2010 - 7 Dec 2010. 116:1051-1052. AMER SOC HEMATOLOGY (19 Nov 2010). Author weblink.
• Pavlu J; Shah R; Auner HW; Milojkovic D; Marin D; Sargent J; Rahemtulla A; MacDonald DH; et alKanfer EJ; Rezvani K; Dazzi F; Goldman JM; Apperley JF; Szydlo RM. Preconditioning Level of C-Reactive Protein and Disease Stage Are Key Prognostic Factors In Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), 4 Dec 2010 - 7 Dec 2010. 116:1433-1434. AMER SOC HEMATOLOGY (19 Nov 2010). Author weblink.
• Holroyd A; Phillips E; Szydlo R; Marin D; Foroni L; Khorashad J; Milojkovic D; Kanfer EJ; et alDazzi F; MacDonald DH; Rahemtulla A; McLornan D; Gabriel IH; Pavlu J; Sargent J; Goldman JM; Apperley JF; Rezvani K. Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), 4 Dec 2010 - 7 Dec 2010. 116:1445-1445. AMER SOC HEMATOLOGY (19 Nov 2010). Author weblink.
• Ersek A; Lymperi S; Dazzi F; Horwood N. Osteoclast activity regulates the size of the haematopoietic stem cell pool. 3rd Joint Meeting of the European-Calcified-Tissue-Society/International-Bone-and-Mineral-Society, 7 May 2011 - 11 May 2011. 48:S124-S124. ELSEVIER SCIENCE INC (7 May 2011). Author weblink DOI.
• Holroyd A; Phillips E; Szydlo R; Mann D; Foroni L; Khorashad J; Milojkovic D; Kanfer EJ; et alDazzi F; MacDonald DH; Rahemtulla A; McLornan D; Gabriel IH; Pavlu J; Sargent J; Goldman JM; Apperley JF; Rezvani K. Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chrome Myeloid Leukemia. 116:1445-1445. (19 Nov 2010).
• Pavlu J; Shah R; Auner HW; Milojkovic D; Sargent DMJ; MacDonald ARDH; Kanfer EJ; Rezvani K; et alDazzi F; Apperley JMGJF; Szydlo RM. Preconditioning Level of C Reactive Protein and Disease Stage Are Key Prognostic Factors In Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation. 116:1433-1434. (19 Nov 2010).
• Rezvani K; Marin D; Goldman JM; Kanfer E; MacDonald D; Dazzi F; Milojkovic D; Rahemtulla A; et alSargeant J; Apperley J; Szydlo R. RISK SCORE PREDICTS OUTCOME OF SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem, 17 Feb 2011 - 21 Feb 2011. 17:S155-S155. ELSEVIER SCIENCE INC (1 Feb 2011). Author weblink DOI.
• Mattoscio M; Nicholas R; Malik O; Mc Guigan C; Dazzi F; Muraro PA. Functional relevance of haematopoietic stem cell mobilization following therapeutic alpha 4-integrin blockade in multiple sclerosis: preliminary data. 20th Meeting of the European-Neurological-Society, 19 Jun 2010 - 23 Jun 2010. 257:S221-S221. SPRINGER HEIDELBERG (1 Jun 2010).
• Siegel G; Schaefer R; Dazzi F. The Immunosuppressive Properties of Mesenchymal Stem Cells. 8th Beaune Seminar in Transplantation Research, 12 Jun 2008 - 13 Jun 2008. 87:S45-S49. LIPPINCOTT WILLIAMS & WILKINS (15 May 2009). Author weblink DOI.
• Pavlu J; Auner H; Szydlo R; Olavarria E; Giles C; Klammer M; Kew A; Milojkovic D; et alGabriel I; Rezvani K; Dazzi F; Marin D; Goldman J; Apperley J. Allogeneic myeloablative haematopoietic stem cell transplantation for chronic myeloid leukaemia in the imatinib era. 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, 29 Mar 2009 - 1 Apr 2009. 43:S49-S49. NATURE PUBLISHING GROUP (1 Mar 2009). Author weblink.
• Pavlu J; Klammer M; Gabriel I; Szydlo R; Olavarria E; Milojkovic D; Kew A; Rezvani K; et alDazzi F; Marin D; Goldman J; Apperley J. Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era. 50th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2008 - 9 Dec 2008. 112:357-357. AMER SOC HEMATOLOGY (16 Nov 2008). Author weblink.
• Lymperi S; Horwood N; Dazzi F. Osteoclast Function Is Essential in the Hematopoietic Stem Cell Niche. 50th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2008 - 9 Dec 2008. 112:205-205. AMER SOC HEMATOLOGY (16 Nov 2008). Author weblink.
• Milojkovic D; Bua M; Apperley JF; Kozlowski K; Sorori J; Foroni L; Reid A; Pavlu J; et alRezvani K; Dazzi F; Olavarria E; Klammer M; Goldman JM; Marin D. Prediction of Cytogenetic Response to Second Generation TKI Therapy in CML Chronic Phase Patients Who Have Failed Imatinib Therapy and Early Identification of Factors That Influence Survival. 50th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2008 - 9 Dec 2008. 112:129-129. AMER SOC HEMATOLOGY (16 Nov 2008). Author weblink.
• Karlsson H; Samarasinghe S; Ball L; Sundberg B; Lankester AC; Dazzi F; Rao K; Veys P; et alLe Blanc K; Ringden O; Amrolia PJ. MESENCHYMAL STEM CELLS EXERT DIFFERENTIAL EFFECTS ON ALLO-ANTIGEN- AND VIRUS-SPECIFIC T CELLS. Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation, 13 Feb 2008 - 17 Feb 2008. 14:48-49. ELSEVIER SCIENCE INC (1 Feb 2008). Author weblink DOI.
• Karlsson H; Samarasinghe S; Ball L; Sundberg B; Lankester AC; Dazzi F; Rao K; Veys P; et alLe Blanc K; Ringden O; Amrolia PJ. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, 30 Mar 2008 - 2 Apr 2008. 41:S15-S16. NATURE PUBLISHING GROUP (1 Mar 2008). Author weblink.
• Tyndall A; Dazzi F; Uccelli A. Multipotent mesenchymal stromal cells in the treatment of autoimmune diseases. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, 30 Mar 2008 - 2 Apr 2008. 41:S7-S7. NATURE PUBLISHING GROUP (1 Mar 2008). Author weblink.
• Avery S; Nadal E; Apperley JF; Olavarria E; Kanfer E; Rahemtulla A; Marin D; Dazzi F; et alSzydlo RM; Goldman JM. Survival beyond 10 years after allogeneic stem cell transplantation (SCT) for CML in chronic phase using HLA-identical sibling or HLA-matched unrelated donors. 45th Annual Meeting of the American-Society-of-Hematology. 102:980A-980A. (16 Nov 2003).
• Nadal E; Fowler A; Avery S; Kanfer E; Apperley J; Goldman J; Dazzi F. Adjuvant IL-2 in the treatment of relapse after allogeneic transplant refractory to donor lymphocyte infusions: clinical and biological effects. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group. 33:S80-S80. (Mar 2004).
• Nadal E; Macchiarulo M; Lim L; Lechler R; Dazzi F. CD4+CD25+ regulatory T-cells favours leukaemia relapse after allogeneic stem cell transplantation. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group. 33:S76-S76. (Mar 2004).
• Laylor R; Dyson P; Dewchand H; Simpson E; Dazzi F. Transplantation tolerance in allogeneic stem cell transplantation with reduced-intensity conditioning. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group. 33:S74-S75. (Mar 2004).
• Glennie SJ; Soeiro I; Dyson J; Lam E; Dazzi F. Mesenchymal stem cells induce division arrest anergy of activated T cells. Joint Meeting of the American-Society-for-Blood-and-Marrow-Transplantation/Center-for-International-Blood-and-Marrow-Transplant-Research. 11:1-1. (Feb 2005).
• Cannella L; Laylor R; Marelli-Berg F; Dazzi F. Irradiation influences endothelial cell function in vitro and in vivo: a possible role of IP10. 31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group. 35:S342-S342. (Mar 2005).
• Tisato V; Naresh K; Navarrete C; Dazzi F. Mesenchymal stem cells are effective at preventing but not at treating GvJD. Tandem BMT Meeting 2007. 13:44-45. (Feb 2007).
• Nadal E; Kaeda J; Apperley JF; Lechler R; Dazzi F. Increased CD4+CD25high+regulatory T-cell are associated with disease relapse after allogeneic stem cell transplantation (SCT) for chronic myeloid leukaemia (CML). Tandem BMT Meeting 2007. 13:15-15. (Feb 2007).
• Fozza C; Nadal E; Longinotti M; Dazzi F. CD4+ CD25+ regulatory T-cells exhibit a higher T-cell receptor diversity than CD4+ CD25- conventional T-cells after allogeneic stem cell transplantation. 33rd Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation. 39:S46-S46. (Apr 2007).
• Tisato V; Naresh K; Girdlestone J; Navarrete C; Dazzi F. Cord blood derived mesenchymal stem cells are effective at preventing graft-versus-host disease. 12th Congress of the European-Hematology-Association. 92:317-317. (Jun 2007).
• Lymperi S; Horwood N; Cope A; Dazzi F. The anabolic effects of strontium increase the number of progenitor but not primitive haemopoietic stem cells. 12th Congress of the European-Hematology-Association. 92:122-122. (Jun 2007).
• Weng L; Dyson J; Dazzi F. Low intensity transplantat regimens facilitate recruitment of donor apecific regulatory T cell which promote heamatopoietic engraftment. 12th Congress of the European-Hematology-Association, 7 Jun 2007 - 10 Jun 2007. 92:379-379. FERRATA STORTI FOUNDATION (1 Jun 2007). Author weblink.
• Jones F; Horwood N; Cope A; Dazzi F. Mesenchymal stem cell mediated immunosuppression is not confined to progenitor status. 12th Congress of the European-Hematology-Association, 7 Jun 2007 - 10 Jun 2007. 92:316-316. FERRATA STORTI FOUNDATION (1 Jun 2007). Author weblink.
• Weng L; Dyson J; Dazzi F. Reduced intensity conditioning allografting induces the generation of antigen-specific regulatory T cells necessary for graft tolerance. Tandem BMT Meeting 2007, 8 Feb 2007 - 12 Feb 2007. 13:104-104. ELSEVIER SCIENCE INC (1 Feb 2007). Author weblink DOI.
• Gorman CL; Zhang Z; Vermi A-C; Monaco C; Marelli-Berg F; Dazzi F; Cope AP. TCR-zeta dim T cells define a population of circulating effector cells that migrate to inflamed tissues. 27th European Workshop for Rheumatology Research, 22 Feb 2007 - 24 Feb 2007. 66:A17-A17. B M J PUBLISHING GROUP (1 Mar 2007). Author weblink.
• Patel KC; Kaeda J; Dazzi F; O'Shea D; Goldman J; Kanfer E; Marin D; Olavarria E; et alRahemtulla A; Apperley J; Salooja N. Low level BCR-ABL transcript positivity in long term survivors of allogeneic stem cell transplantation for CIVIL. 45th Annual Scientific Meeting of the British-Society-for-Haematology, 11 Apr 2005 - 13 Apr 2005. 129:75-75. BLACKWELL PUBLISHING (1 Apr 2005). Author weblink.
• O'Shea DM; Kaeda J; Szydlo R; Olavarria E; Marin D; Dazzi F; Perz JB; Anand M; et alSaunders S; Goldman JM; Apperley JF. Variable significance of low levels of Bcr-Abl transcripts in the peripheral blood after allogeneic stem cell transplant for chronic myeloid leukaemia in chronic phase. 31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, 20 Mar 2005 - 23 Mar 2005. 35:S68-S69. NATURE PUBLISHING GROUP (1 Mar 2005). Author weblink.
• Cannella L; Laylor R; Marelli-Berg F; Dazzi F. Irradiation influences endothelial cell function in vitro and in vivo: A possible role for IP10. Joint Meeting of the American-Society-for-Blood-and-Marrow-Transplantation/Center-for-International-Blood-and-Marrow-Transplant-Research, 10 Feb 2005 - 14 Feb 2005. 11:45-45. CARDEN JENNINGS PUBL CO LTD (1 Feb 2005). Author weblink DOI.
• Zhang Z; Panesar M; Amjadi P; Foey A; Owen S; Dazzi F; Brennan FM; Cope AP. Sustained downregulation of the TCR zeta chain defines a transition from antigen mode to inflammation mode during terminal T-cell differentiation. 25th European Workshop for Rheumatology Research, 24 Feb 2005 - 27 Feb 2005. 7:S30-S30. BIOMED CENTRAL LTD (1 Feb 2005). Author weblink DOI.
• Nadal E; Marktel S; Szydlo R; Olavarria E; Kanter E; Rahemtulla A; Apperley J; Goldman J; et alDazzi F. Impact of GvHD in long-term remission after escalated donor lymphocyte infusions. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, 28 Mar 2004 - 31 Mar 2004. 33:S178-S178. NATURE PUBLISHING GROUP (1 Mar 2004). Author weblink.
• Glennie S; Soeiro I; Lam E; Dazzi F. Mesenchymal stem cells inhibit immune responses by arresting T-cell proliferation in the G1 phase of the cell cycle. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, 28 Mar 2004 - 31 Mar 2004. 33:S15-S15. NATURE PUBLISHING GROUP (1 Mar 2004). Author weblink.
• Cannella L; Laylor R; Dewchand H; Simpson E; Marelli-Berg F; Dazzi F. The conditioning regimen influences migration of donor T-cells in recipient tissues. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, 28 Mar 2004 - 31 Mar 2004. 33:S176-S176. NATURE PUBLISHING GROUP (1 Mar 2004). Author weblink.
• Guglielmi C; Arcese W; Dazzi F; Brand R; Bunjes D; Verdonck LF; Schattenberg A; Kolb HJ; et alLjungman P; Devergie A; Bacigalupo A; Gomez M; Michallet M; Elmaagacli A; Gratwohl A; Apperley J; Niederwieser D. Low initial cell dose and escalating dose regimen is the best method of administering unmanipulated donor lymphocytes for relapsed chronic myelogenous leukemia. 44th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2002 - 10 Dec 2002. 100:635A-635A. AMER SOC HEMATOLOGY (16 Nov 2002). Author weblink.